Head-to-head evidence
NK510 vs Sea-tgt
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: TIGIT · full Non-Small Cell Lung Cancer pipeline
NK510
Developed by Base Therapeutics (Shanghai) Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2027 · NCT06097962 (registry estimate)
Sea-tgt
Developed by Seagen
NCT04254107 · Phase 1 · terminated
This is an open-label, non-randomized, single-arm Phase 1 study testing SEA-TGT alone or combined with other agents across a wide range of advanced cancers, with no control group. It is designed to establish a safe dose and monitor toxicity, not to test efficacy, and results have not yet been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NK510's landscape · Sea-tgt's landscape